ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Chinese expert consensus on the application of flow cytometry in the diagnosis and detection of minimal residual disease in B-cell non-Hodgkin lymphoma (2025)].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell non-Hodgkin lymphoma (B-NHL) is made up of multiple subtypes, whose precise diagnosis relies on multidisciplinary collaboration, including pathological morphology, immunohistochemistry, flow cytometry (FCM), cytogenetics, molecular biology, imaging and clinical features. FCM plays an irreplaceable role in the diagnosis of B-NHL and minimal/measurable residual disease (MRD) monitoring due to its unique advantages of simplicity, rapidness, objectivity, high sensitivity, and multi-parameter analysis. With the publication of the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours and the International Consensus Classification (ICC), the classification of B-NHL has become more refined, with significant changes in some classification methods and nomenclature. To improve the diagnostic and therapeutic monitoring ability of B-NHL and standardize the diagnosis and treatment procedures of B-NHL in China, the Hematological Oncology Committee of the China Anti-Cancer Association organized relevant domestic experts to develop this expert consensus after multiple discussions. The consensus focuses on the application of FCM in the diagnosis and MRD detection of mature B-NHL including the sources and preparation of samples for FCM, the immunophenotypic characteristics of different subclasses of B-NHL, result analysis and reporting, and quality control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.